346 related articles for article (PubMed ID: 24141856)
1. In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors.
Thomsen R; Rasmussen HB; Linnet K;
Drug Metab Dispos; 2014 Jan; 42(1):126-33. PubMed ID: 24141856
[TBL] [Abstract][Full Text] [Related]
2. Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril.
Zhu HJ; Appel DI; Johnson JA; Chavin KD; Markowitz JS
Biochem Pharmacol; 2009 Apr; 77(7):1266-72. PubMed ID: 19185566
[TBL] [Abstract][Full Text] [Related]
3. In vitro hydrolysis and transesterification of CDP323, an α4β1/α4β7 integrin antagonist ester prodrug.
Chanteux H; Rosa M; Delatour C; Prakash C; Smith S; Nicolas JM
Drug Metab Dispos; 2014 Jan; 42(1):153-61. PubMed ID: 24179032
[TBL] [Abstract][Full Text] [Related]
4. CES1P1 variant -816A>C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril.
Zhu HJ; Langaee TY; Gong Y; Wang X; Pepine CJ; Cooper-DeHoff RM; Johnson JA; Markowitz JS
Eur J Clin Pharmacol; 2016 Jun; 72(6):681-7. PubMed ID: 26915813
[TBL] [Abstract][Full Text] [Related]
5. CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors.
Wang X; Wang G; Shi J; Aa J; Comas R; Liang Y; Zhu HJ
Pharmacogenomics J; 2016 Jun; 16(3):220-30. PubMed ID: 26076923
[TBL] [Abstract][Full Text] [Related]
6. Conclusive identification of the oxybutynin-hydrolyzing enzyme in human liver.
Sato Y; Miyashita A; Iwatsubo T; Usui T
Drug Metab Dispos; 2012 May; 40(5):902-6. PubMed ID: 22293119
[TBL] [Abstract][Full Text] [Related]
7. Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis.
Laizure SC; Parker RB; Herring VL; Hu ZY
Drug Metab Dispos; 2014 Feb; 42(2):201-6. PubMed ID: 24212379
[TBL] [Abstract][Full Text] [Related]
8. Presence and inter-individual variability of carboxylesterases (CES1 and CES2) in human lung.
Gabriele M; Puccini P; Lucchi M; Vizziello A; Gervasi PG; Longo V
Biochem Pharmacol; 2018 Apr; 150():64-71. PubMed ID: 29407485
[TBL] [Abstract][Full Text] [Related]
9. Contribution of human esterases to the metabolism of selected drugs of abuse.
Meyer MR; Schütz A; Maurer HH
Toxicol Lett; 2015 Jan; 232(1):159-66. PubMed ID: 25445008
[TBL] [Abstract][Full Text] [Related]
10. Characterization of recombinant human carboxylesterases: fluorescein diacetate as a probe substrate for human carboxylesterase 2.
Wang J; Williams ET; Bourgea J; Wong YN; Patten CJ
Drug Metab Dispos; 2011 Aug; 39(8):1329-33. PubMed ID: 21540359
[TBL] [Abstract][Full Text] [Related]
11. Different hydrolases involved in bioactivation of prodrug-type angiotensin receptor blockers: carboxymethylenebutenolidase and carboxylesterase 1.
Ishizuka T; Yoshigae Y; Murayama N; Izumi T
Drug Metab Dispos; 2013 Nov; 41(11):1888-95. PubMed ID: 23946449
[TBL] [Abstract][Full Text] [Related]
12. Difference in substrate specificity of carboxylesterase and arylacetamide deacetylase between dogs and humans.
Yoshida T; Fukami T; Kurokawa T; Gotoh S; Oda A; Nakajima M
Eur J Pharm Sci; 2018 Jan; 111():167-176. PubMed ID: 28966098
[TBL] [Abstract][Full Text] [Related]
13. Effects of alcohol on human carboxylesterase drug metabolism.
Parker RB; Hu ZY; Meibohm B; Laizure SC
Clin Pharmacokinet; 2015 Jun; 54(6):627-38. PubMed ID: 25511794
[TBL] [Abstract][Full Text] [Related]
14. Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions.
Zhu HJ; Appel DI; Peterson YK; Wang Z; Markowitz JS
Toxicology; 2010 Apr; 270(2-3):59-65. PubMed ID: 20097249
[TBL] [Abstract][Full Text] [Related]
15. Screening of specific inhibitors for human carboxylesterases or arylacetamide deacetylase.
Shimizu M; Fukami T; Nakajima M; Yokoi T
Drug Metab Dispos; 2014 Jul; 42(7):1103-9. PubMed ID: 24751575
[TBL] [Abstract][Full Text] [Related]
16. Comparison of substrate specificity among human arylacetamide deacetylase and carboxylesterases.
Fukami T; Kariya M; Kurokawa T; Iida A; Nakajima M
Eur J Pharm Sci; 2015 Oct; 78():47-53. PubMed ID: 26164127
[TBL] [Abstract][Full Text] [Related]
17. Rapid conversion of the new angiotensin converting enzyme inhibitor ramipril to its active metabolite in rats.
Tabata S; Yamazaki H; Ohtake Y; Hayashi S
Arzneimittelforschung; 1990 Aug; 40(8):865-7. PubMed ID: 2173610
[TBL] [Abstract][Full Text] [Related]
18. Carboxylesterase-2 plays a critical role in dabigatran etexilate active metabolite formation.
Laizure SC; Chen F; Farrar JE; Ali D; Yang B; Parker RB
Drug Metab Pharmacokinet; 2022 Dec; 47():100479. PubMed ID: 36375226
[TBL] [Abstract][Full Text] [Related]
19. Impact of endogenous esterase activity on in vitro p-glycoprotein profiling of dabigatran etexilate in Caco-2 monolayers.
Ishiguro N; Kishimoto W; Volz A; Ludwig-Schwellinger E; Ebner T; Schaefer O
Drug Metab Dispos; 2014 Feb; 42(2):250-6. PubMed ID: 24212377
[TBL] [Abstract][Full Text] [Related]
20. A Comprehensive Functional Assessment of Carboxylesterase 1 Nonsynonymous Polymorphisms.
Wang X; Rida N; Shi J; Wu AH; Bleske BE; Zhu HJ
Drug Metab Dispos; 2017 Nov; 45(11):1149-1155. PubMed ID: 28838926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
